瑞巴派特片对治疗幽门螺旋杆菌阳性消化性溃疡效果与复发的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (738 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influence of ribapamide on the therapeutic effect and recurrence of helicobacter pylori (HP) - positive peptic ulcer. Methods Between October 2018 and September 2019, 110 patients with Helicobacter pylori positive peptic ulcer admitted to Beijing Municipal Corps Hospital of PAP were selected as the subjects. Sixty-two of these patients were treated with conventional quadruple sterilization and included in the control group, while the rest were additionally treated with ribapamide and included in the study group. Both groups were treated for two consecutive weeks. After treatment, the HP eradication rate and the therapeutic effect were detected and compared between the two groups. After treatment, patients in both groups were followed up for a minimum of six months. The number of HP positive cases during follow-up and the HP recurrence rate of the two groups were calculated. The serum levels of IL-6, TNF-a and CRP and other inflammation factors, hematocrit, RBC aggregation index, plasma viscosity and erythrocyte sedimentation rate and other hemorheological indexes before treatment and two weeks after treatment were measured and compared between the two groups. The rate of adverse reactions or complications was also compared between the two groups. Results The effective rate and eradication rate of HP in the study group were 95.83% and 95.83% respectively, which were higher than 80.65% and 82.26% in the control group. The recurrence rate of HP in the study group was 10.87%, which was lower than 27.45% in the control group (P<0.05). After two weeks of treatment, the serum IL-6 value was (9.11±1.66)ng/L, TNF-α value(1.25±0.25)μg/L and CRP value was(3.55±1.06)mg/L in the study group, compared to(13.74±2.03)ng/L,(2.17±0.34)μg/L and(5.26±1.43)mg/L in the control group, so the difference was statistically significant (P<0.05). After two weeks of treatment, serum levels of IL-6, TNF-α and CRP, hematocrit, erythrocyte aggregation index, plasma viscosity and erythrocyte sedimentation rate of the two groups decreased (P<0.05). There was no significant difference in the rate of adverse reactions or complications between the two groups. Conclusions The efficacy and safety of rebamipide tablets combined with conventional quadruple sterilization in the treatment of Hp-positive peptic ulcer are satisfactory, which can improve hemorheology, alleviate inflammatory reactions and prevent Hp recurrence. This approach should be made accessible.

Key words： ribapamide tablets helicobacter pylori positive peptic ulcer therapeutic effect recurrence

Received: 11 March 2020

ZTFLH:

R573.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PENG Le¹
	ZHANG Ya²
	CHANG Haisheng¹

Cite this article:

PENG Le¹,ZHANG Ya²,CHANG Haisheng¹. Influence of ribapamide on curative effect and recurrence of helicobacter pylori positive peptic ulcer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(9): 789-792.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I9/789

[1]	Kavitt R T, Lipowska A M, Anyane-Yeboa A, et al. Diagnosis and treatment of peptic ulcer disease[J]. Am J Med, 2019, 132(4):447-456.
[2]	Lukš M. Therapy for peptic ulcer disease[J]. Vnitr Lek, 2018, 64(6):595-599.
[3]	熊愫兵,田莉,郑晓春,等.瑞巴派特联合泮托拉唑治疗幽门螺杆菌阴性慢性糜烂性胃炎的临床疗效研究[J]. 临床和实验医学杂志, 2014(24):2015-2018.
[4]	叶任高,陆再英.内科学[M].北京:人民卫生出版社,2005: 385.
[5]	卢玉龙,吴旻,陈开德, 等.兰索拉唑联合碳酸铝镁片与呋喃唑酮治疗幽门螺旋杆菌阳性消化道溃疡的疗效观察[J]. 临床医药文献电子杂志, 2019, 6(22): 7-9.
[6]	Gouta E L, Dougaz W, Khalfallah M, et al. Management of perforated duodenal peptic ulcer treated by suture[J]. Tunis Med, 2018, 96(7):424-429.
[7]	Mousa A M, El-Sammad N M, Hassan S K, et al. Antiulcerogenic effect of cuphea ignea extract against ethanol-induced gastric ulcer in rats[J]. BMC Complement Altern Med, 2019, 19(1):345.
[8]	Almeida L R, Costa P S, Nascimento A M A, et al. Porcine stomachs with and without gastric ulcer differ in Lactobacillus load and strain characteristics[J]. Can J Microbiol, 2018, 64(7): 493-499.
[9]	蔡传运.小柴胡汤加减联合健胃化瘀汤对反复性消化性溃疡血清生长因子水平的影响[J].实用临床医药杂志,2020,24(1):54-57.
[10]	龚世富.瑞巴派特联合胃三联治疗消化道溃疡的疗效观察[J].家庭医药,2019 (1):75-76.
[11]	高川,何志刚,马敏俊, 等.不同抗溃疡药物对非甾体类抗炎药相关性溃疡复发的预防效果比较[J].中国乡村医药,2019, 26(6):14-15.
[12]	刘庆东,赵纯梅,王蒙, 等.泮托拉唑联合瑞巴派特治疗慢性糜烂性胃炎的疗效[J].贵州医药,2019,43(11):1765-1766.
[13]	罗雪,高青.瑞巴派特治疗NSAIDs相关性胃肠道不良反应疗效的Meta分析[J].世界最新医学信息文摘(连续型电子期刊),2019, 19(43):15-17,20.
[14]	段兆涛,张振玉,吴海露, 等.瑞巴派特对阿司匹林所致人胃黏膜上皮细胞损伤的保护作用及其机制[J].中华消化杂志,2014,34(7): 453-457.
[15]	程玉强.瑞巴派特三联疗法治疗胃溃疡伴胃出血效果观察[J].临床合理用药杂志, 2019, 12(22): 68-69.
[16]	魏丽娟,刘佰纯,白东梅, 等.胃镜电凝止血联合瑞巴派特三联疗法治疗胃溃疡出血的疗效[J].南昌大学学报(医学版),2019, 59(5):67-69.
[17]	刘少康,马燕,赵翠霞.自拟胃复汤对不同证型消化性溃疡胃泌素和血液流变学的影响[J].吉林中医药,2020,40(2):197-200.